Akebia Therapeutics, Inc.
AKBAAkebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for patients with kidney disease. The company's lead product, vadadustat, is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor intended to treat anemia associated with chronic kidney disease. Akebia aims to address unmet medical needs in renal conditions through innovative treatments.
Company News
The acute kidney injury (AKI) therapeutic pipeline is experiencing robust growth with 20+ pharmaceutical companies developing 25+ pipeline drugs across various clinical stages. Key players including AstraZeneca, Arch Biopartners, Akebia Therapeutics, and others are advancing promising therapies with diverse mechanisms of action. Recent developmen...
Akebia Therapeutics announced it will release its Q4 and full year 2025 financial results on February 26, 2026, followed by a conference call at 8:00 a.m. EST to discuss financial results and recent business highlights.
Akebia Therapeutics announced that its executive team will participate in a Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026. The company, focused on kidney disease treatments, will discuss its pipeline outlook including Vafseo prescribing expansion and Praliciguat Phase 2 clinical trial progress.
Q32 Bio sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics for $12 million in upfront payments, with potential milestone payments up to $592 million, causing its stock to surge by over 115%.
Akebia Therapeutics presented a post-hoc win-odds analysis of vadadustat in dialysis patients, demonstrating statistically significant favorable outcomes compared to darbepoetin alfa in mortality and hospitalization metrics.
